Celldex Therapeutics

CLDXNasdaq United States Health Care Biotechnology: In Vitro & In Vivo Diagnostic Substances

Market cap

$2.975 B

$37.89 -0.92%

Close of 21 Sept 2026

Revenue

$1.54M

#3444 by revenue

Earnings

-$258.8M

Loss-making

Shares outstanding

78,529,532

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: In Vitro & In Vivo Diagnostic Substances, ranked by market cap

All 19 →

#2LantheusLNTH$6.55B
#3Oruka TherapeuticsORKA$6.18B
#4Celldex TherapeuticsCLDX$2.98B
#5NeogenNEOG$2.97B
#6Intellia TherapeuticsNTLA$1.71B

What if Celldex Therapeutics were worth as much as…

Open the what-if tool →

Gold $30.3T

$385,511.71

Per share 10,174× higher

Bitcoin $1.72T

$21,900.09

Per share 578× higher

Nvidia $5.48T

$69,780.86

Per share 1,842× higher

Or at a round number

$5.00B $10.0B $20.0B $50.0B

Where these numbers come from

Share counts and financials for Celldex Therapeutics are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 22 Sept 2026. Read the methodology.